Koers Point Capital Inc Other OTC
Aandelen
US73052R1041
Farmaceutische producten
Omzet 2024 * | 72K 66,86K | Omzet 2025 * | 72K 66,86K | Marktkapitalisatie | 4,78 mln. 4,44 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -3,71 mln. | Nettowinst (verlies) 2025 * | -8 mln. -7,43 mln. | EV/omzet 2024 * | 66,4 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 66,4 x |
K/w-verhouding 2024 * |
-3
x | K/w-verhouding 2025 * |
-2,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 86,01% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13-07-10 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 27-09-22 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 01-09-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 13-07-10 |
Wayne Linsley
BRD | Director/Board Member | 67 | 16-01-20 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 01-10-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,61% | 89,08 mld. | |
+3,55% | 40,9 mld. | |
-14,40% | 32,25 mld. | |
+55,89% | 25,14 mld. | |
-15,96% | 15,39 mld. | |
-15,50% | 11,91 mld. | |
-41,29% | 11,89 mld. | |
-11,75% | 11,64 mld. | |
+7,87% | 9,03 mld. |